FDA
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating For Agile Therapeutics (NASDAQ: AGRX), Citing Growing Demand For Twirla, A Weekly Low Dose Birth Control Patch
-
-
-
-
-
-
-
Agile Therapeutics Announces Findings of First-Year Post-Marketing Pharmacovigilance in ACOG Poster Presentation
-
-
-
-
-
-
-
Agile Therapeutics Reports Third Quarter 2021 Financial Results
-
-
-
-
-
-
-
Agile Therapeutics Reports Fourth Quarter & Full Year 2020 Financial Results; Expands Loan Facility With Perceptive Advisors
-
-
-
-
-
-
-
Agile Therapeutics Announces Peer-Reviewed Publication of Phase 3 SECURE Study Results for Twirla® (levonorgestrel and ethinyl estradiol) Transdermal System in Contraception
-
-
-
-
-
-
-
Pre-Open Stock Movers 02/21: (BXRX) (CRC) (DBX) Higher (TRUE) (BXC) (EYPT) Lower (more...)
-
-
-
-
-
-
-
Agile Therapeutics (AGRX) Announces FDA Approval of Twirla Transdermal System
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

